Biotechnology

The company is working on regulatory approvals in the U.S. and China.

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

Akorn shares plummeted Monday after Germany's Fresenius Medical ditched its planned $5 billion takeover amid allegations of data misconduct at the Lake Forest, Ill.-based generic drugmaker.

What was once a red and blue issue has now attracted a growing set of proponents from both sides of the aisle. Here's what that could mean for regulation of legal cannabis in the U.S.

Ultragenyx scored its second FDA drug approval in six months. The orphan disease specialist also picked up its second Rare Pediatric Disease Priority Review Voucher; its first sold for $130 million.

Jim Cramer and our other experts discuss Friday jitters, trading the missile strike, and oncology stocks to watch.

Deals in biopharma slowed in 2017 for the third consecutive year. According to Intec Pharma CEO Jeffrey Meckler, just because volume is down doesn't mean it's out.

Jim Cramer and our other experts discuss the FAANG stocks, a market bottom, and potential biotech targets.

Here's what you need to know for Monday, April 9.

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.